DLD Asset Management’s PTC Therapeutics PTCT Stock Holding History

DLD Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-612,543	Closed	-$12.3M	–	96
2017 Q3	$12.3M	Buy	+612,543	New	+$12M	1.21%	20

Other funds holding PTCT

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

SIM

Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return

DLD Asset Management's PTCT Position: Q4 2017 in Review

DLD Asset Management sold out of PTC Therapeutics (PTCT) in Q4 2017, closing a stake of 612,543 shares — an estimated $12.3M sold.

DLD Asset Management first reported a position in PTCT in Q3 2017 and held it in 1 quarter. The position peaked at $12.3M in Q3 2017. 125 funds tracked by Wall St. Rank hold PTCT as of Q4 2017.

DLD Asset Management reported no remaining PTC Therapeutics position as of Q4 2017 after selling out during the quarter.
DLD Asset Management sold 612,543 PTC Therapeutics shares in Q4 2017, an estimated $12.3M.
DLD Asset Management first reported a position in PTC Therapeutics in Q3 2017 and held it in 1 quarter.
DLD Asset Management's PTC Therapeutics position peaked at $12.3M in Q3 2017.
125 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2017.

Based on DLD Asset Management's 13F filing for Q4 2017, filed 12 Feb 2018.